Login Register Cart 0
Review Article

Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity - Associated Cancers

Author(s): Kinga Majchrzak*, Marta Piotrowska, Julia Krajewska and Jakub Fichna

Volume 23, Issue 6, 2022

Published on: 12 July, 2021

Page: [597 - 605] Pages: 9

DOI: 10.2174/1389450122666210712193654

Price: $65

Abstract

Fatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regulating metabolism in obese people. Recent studies in mouse models and humans demonstrated the role of A-FABP in increasing the risk of obesity-related cancers. Here we summarized the state of research on the link between obesity, cancer and A-FABP as a new potential therapeutic target for the treatment of obesity - associated cancers.

Keywords: Fatty acid binding proteins, adipocytes, cancer, obesity, metabolic syndrome, metabolism.

« Previous Next »
Graphical Abstract

[1]
Kucharski M, Kaczor U. Fatty acid binding protein 4 (FABP4) and the body lipid balance. Folia Biol 2017; 65(4): 181-6.
[http://dx.doi.org/10.3409/fb65_4.181]
[2]
Harasim E, Kalinowska A, Stępek T, Chabowski A. Udział białek transportujących (FAT / CD36, FABPpm, FATP) w metabolizmie lipidów w mięśniach szkieletowych The role of fatty-acid transport proteins (FAT / CD36, FABPpm, FATP) in lipid metabolism in skeletal muscles. Postep Hig Med Dosw Online 2008; 433-41.
[3]
Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 2002; 59(7): 1096-116.
[http://dx.doi.org/10.1007/s00018-002-8490-y] [PMID: 12222958]
[4]
Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H, Scheffold T. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010; 105(1): 1-9.
[http://dx.doi.org/10.1016/j.amjcard.2009.08.645] [PMID: 20102882]
[5]
Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept 2008; 147(1-3): 25-8.
[http://dx.doi.org/10.1016/j.regpep.2007.12.002] [PMID: 18201778]
[6]
Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009; 32(1): 147-52.
[http://dx.doi.org/10.2337/dc08-1379] [PMID: 18835952]
[7]
Engl J, Ciardi C, Tatarczyk T, et al. A-FABP-a biomarker associated with the metabolic syndrome and/or an indicator of weight change? Obesity (Silver Spring) 2008; 16(8): 1838-42.
[http://dx.doi.org/10.1038/oby.2008.273] [PMID: 18535557]
[8]
Zeng J, Sauter ER, Li B. FABP4: A new player in obesity-associated breast cancer. Trends Mol Med 2020; 26(5): 437-40.
[http://dx.doi.org/10.1016/j.molmed.2020.03.004] [PMID: 32359475]
[9]
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20(2): 12.
[http://dx.doi.org/10.1007/s11906-018-0812-z] [PMID: 29480368]
[10]
Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. Int J Obes 2011; 35(3): 393-400.
[http://dx.doi.org/10.1038/ijo.2010.152] [PMID: 20680014]
[11]
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
[http://dx.doi.org/10.1016/S0140-6736(05)66378-7] [PMID: 15836891]
[12]
Wagh A, Stone NJ. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther 2004; 2(2): 213-28.
[http://dx.doi.org/10.1586/14779072.2.2.213] [PMID: 15151470]
[13]
Gormez S, Erdim R, Akan G, et al. Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome. Cardiovasc Pathol 2020; 46: 107192.
[http://dx.doi.org/10.1016/j.carpath.2019.107192] [PMID: 31927390]
[14]
Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1(2): 107-19.
[http://dx.doi.org/10.1016/j.cmet.2004.12.008] [PMID: 16054052]
[15]
Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs-mechanisms and therapeutic implications. Nat Rev Endocrinol 2015; 11(10): 592-605.
[http://dx.doi.org/10.1038/nrendo.2015.122] [PMID: 26260145]
[16]
Prentice KJ, Saksi J, Hotamisligil GS. Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses. J Lipid Res 2019; 60(4): 734-40.
[http://dx.doi.org/10.1194/jlr.S091793] [PMID: 30705117]
[17]
Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues. Diabetes 2014; 63(3): 900-11.
[http://dx.doi.org/10.2337/db13-0436] [PMID: 24319114]
[18]
Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 2000; 275(24): 18527-33.
[http://dx.doi.org/10.1074/jbc.M001297200] [PMID: 10748014]
[19]
Tryggestad JB, Teague AM, Sparling DP, Jiang S, Chernausek SD. Macrophage-derived microrna-155 increases in obesity and influences adipocyte metabolism by targeting peroxisome proliferator-activated receptor gamma. Obesity 2019; 27(11): 1856-64.
[http://dx.doi.org/10.1002/oby.22616] [PMID: 31531958]
[20]
Chow WS, Tso AWK, Xu A, et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. J Am Heart Assoc 2013; 2(1): e004176.
[http://dx.doi.org/10.1161/JAHA.112.004176] [PMID: 23525430]
[21]
Tso AWK, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30(10): 2667-72.
[http://dx.doi.org/10.2337/dc07-0413] [PMID: 17620449]
[22]
Yamashita K, Yamamoto MH, Igawa W, et al. Association of epicardial adipose tissue volume and total coronary plaque burden in patients with coronary artery disease. Int Heart J 2018; 59(6): 1219-26.
[http://dx.doi.org/10.1536/ihj.17-709] [PMID: 30369579]
[23]
Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447(7147): 959-65.
[http://dx.doi.org/10.1038/nature05844] [PMID: 17554340]
[24]
Furuhashi M, Yuda S, Muranaka A, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J 2018; 82(4): 1121-9.
[http://dx.doi.org/10.1253/circj.CJ-17-1295] [PMID: 29445067]
[25]
Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. NNat Med 2001; 7(6): 699-705.
[26]
Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10(8): 455-65.
[http://dx.doi.org/10.1038/nrendo.2014.94] [PMID: 24935119]
[27]
Quispe-Tintaya W. HHS public access. Physiol Behav 2017; 176(3): 139-48.
[28]
Hao J, Zhang Y, Yan X, et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab 2018; 28(5): 689-705.e5.
[http://dx.doi.org/10.1016/j.cmet.2018.07.006] [PMID: 30100196]
[29]
Cui Y, Song M, Kim SY. Prognostic significance of fatty acid binding protein-4 in the invasive ductal carcinoma of the breast. Pathol Int 2019; 69(2): 68-75.
[http://dx.doi.org/10.1111/pin.12756] [PMID: 30694572]
[30]
Tucker SL, Gharpure K, Herbrich SM, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 2014; 20(12): 3280-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0445] [PMID: 24756370]
[31]
Gharpure KM, Pradeep S, Sans M, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 2018; 9(1): 2923.
[http://dx.doi.org/10.1038/s41467-018-04987-y] [PMID: 30050129]
[32]
Mukherjee A, Chiang CY, Daifotis HA, et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res 2020; 80(8): 1748-61.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-1999] [PMID: 32054768]
[33]
Chiyonobu N, Shimada S, Akiyama Y, et al. Fatty acid binding protein 4 (fabp4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors. Am J Pathol 2018; 188(5): 1213-24.
[http://dx.doi.org/10.1016/j.ajpath.2018.01.012] [PMID: 29454748]
[34]
Laouirem S, Sannier A, Norkowski E, et al. Endothelial fatty liver binding protein 4: A new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene 2019; 38(16): 3033-46.
[http://dx.doi.org/10.1038/s41388-018-0597-1] [PMID: 30575815]
[35]
Thompson KJ, Austin RG, Nazari SS, Gersin KS, Iannitti DA, McKillop IH. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int 2018; 38(6): 1074-83.
[http://dx.doi.org/10.1111/liv.13639] [PMID: 29171144]
[36]
Nie J, Zhang J, Wang L, et al. Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. J Exp Clin Cancer Res 2017; 36(1): 183.
[http://dx.doi.org/10.1186/s13046-017-0641-y] [PMID: 29237483]
[37]
Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11(12): 886-95.
[http://dx.doi.org/10.1038/nrc3174] [PMID: 22113164]
[38]
Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochim Biophys Acta 2011; 1807(6): 664-78.
[http://dx.doi.org/10.1016/j.bbabio.2010.11.004] [PMID: 21111705]
[39]
Freeman. HHS public access. Physiol Behav 2018; 176(1): 139-48.
[40]
Uehara H, Takahashi T, Oha M, Ogawa H, Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer 2014; 135(11): 2558-68.
[41]
Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA. Obesity, body composition, and prostate cancer. BMC Cancer 2012; 12.
[42]
Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23(7): 1665-71.
[43]
Kristal AR, Gong Z. Obesity and prostate cancer mortality. Futur Oncol 2007; 3(5): 557-67.
[44]
Celis JE, Østergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996; 56(20): 4782-90.
[PMID: 8840999]
[45]
Ohlsson G, Moreira JMA, Gromov P, Sauter G, Celis JE. Loss of expression of the adipocyte-type fatty acid-binding protein (AFABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 2005; 4(4): 570-81.
[http://dx.doi.org/10.1074/mcp.M500017-MCP200] [PMID: 15734831]
[46]
Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009; 124(8): 1820-8.
[http://dx.doi.org/10.1002/ijc.24112] [PMID: 19115207]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy